Investor Presentaiton slide image

Investor Presentaiton

EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) <30% Illustrative >30% Future drivers of EBIT margin EBIT will be positively impacted by: + Leverage effect on fixed costs e.g. distribution, admin and R&D costs especially driven by Europe EBIT will be negatively impacted by: Investments in P/L (Commercial & R&D) Incremental investment of up to 2% of revenue per year Remainder of A Gross margin Strive25 Leverage effect/scale Incremental investments EBIT margin beyond 24/252 strategic period on fixed costs 1) 2) 41 Constant exchange rates For the remaining Strive25 strategic period running until end 2024/25, the EBIT margin is now expected to remain below 30%, and assumes dilution of around 100 basis points p.a. from Kerecis (including PPA amortisation) FY 2021/22 and FY 2022/23 headwind on gross margin from increasing prices for raw materials, energy, freight, and wage inflation in Hungary The acquisition of Kerecis is expected to be short- term dilutive to the EBIT margin, with around 100 basis points impact p.a. (including PPA amortisation) in the Strive25 strategic period Coloplast
View entire presentation